During the past decade, Chattanooga Oncology Hematology Associates conducted 18 clinical trials. In the 10-year time frame, 18 clinical trials started and 55 clinical trials were completed, i.e. on average, 305.6% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 15 clinical trials were completed. i.e. 214.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chattanooga Oncology Hematology Associates" #1 sponsor was "SCRI Development Innovations, LLC" with 48 trials, followed by "Novartis Pharmaceuticals" with 13 trials sponsored, "Bristol-Myers Squibb" with 5 trials sponsored, "Celgene" with 5 trials sponsored and "Eli Lilly and Company" with 5 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chattanooga Oncology Hematology Associates" #1 collaborator was "Genentech, Inc." with 17 trials as a collaborator, "GlaxoSmithKline" with 6 trials as a collaborator, "Novartis" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator and "Eli Lilly and Company" with 4 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Chattanooga Oncology Hematology Associates" are "Breast Cancer" (14 trials), "Non Small Cell Lung Cancer" (8 trials), "Non-Small Cell Lung Cancer" (6 trials), "Metastatic Breast Cancer" (4 trials) and "Prostate Cancer" (4 trials). Many other conditions were trialed in "Chattanooga Oncology Hematology Associates" in a lesser frequency.

Most popular intervention types in "Chattanooga Oncology Hematology Associates" are "Drug" (100 trials), "Biological" (4 trials), "Procedure" (4 trials), "Other" (3 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (14 trials), "Carboplatin" (13 trials), "Gemcitabine" (10 trials), "Paclitaxel" (9 trials) and "Placebo" (9 trials). Other intervention names were less common.

The vast majority of trials in "Chattanooga Oncology Hematology Associates" are 82 trials for "All" genders, 17 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Chattanooga Oncology Hematology Associates". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 79 completed trials in Chattanooga Oncology Hematology Associates, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Chattanooga Oncology Hematology Associates, 4 "Phase 1" clinical trials were conducted, 70 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".